|Thursday, 9 November 2006|
ASX-listed Solagran has announced that trials recently completed at Swinburne University's Brain Sciences Institute in Melbourne have shown that three months of treatment with its drug Ropren led to a minimum 15% improvement in memory in healthy elderly people.
The double blind, placebo controlled trial was conducted by a team led by BSI director Professor Con Stough and involved just under 100 participants aged between 60 and 85.
Initial results from the trial were presented on Tuesday by Stough at the Worldnutra Conference in Reno, Nevada.
According to Solagran executive chairman Dr Vagif Soultanov, the results are consistent with human trials conducted in Russia with Alzheimer's patients in 2005 and with chronic alcoholics earlier this year.
The Russian Alzheimer's trial was conducted at the Skvortsova-Stepanova Psychiatric Hospital in St Petersburg, under the supervision of the hospital's head clinician, Dr Vladimir Agishev.
It involved 40 patients who had been suffering from Alzheimer's type dementia for between six months and four years. Twenty-five were given Ropren and 15 were given a comparator Gliatilin (choline alphoscerate).
Four months of treatment with Ropren led to an average 38% improvement in cognitive function based on the Mini Mental State Examination (MMSE), together with the elimination of most of the other symptoms, including depression.
Eleven patients experienced an improvement of 50% or more in their MMSE score. Six experienced an improvement of 100% or more.
In briefing the Solagran board on the results of the Swinburne trials, Stough said that he had been extremely sceptical about the claims being made about Ropren as a result of previous trials.
"But I now think that the effect of treatment with Ropren is really impressive," he said.
"These results are outstanding and need to be communicated to the public."
Five different sets of tests were employed in the Swinburne trial, including blood biochemical analysis, batteries of neuropsychological and mood tests, computerised brain analyses and EEGs.
In addition to the improvement in memory, the Australian trials showed that treatment with Ropren also led to a marked improvement in liver function and to a normalisation of cholesterol levels. There were no adverse outcomes or side effects noted.
Ropren is a natural substance containing polyprenols that Solagran obtains from green conifer needles – using a patented extraction technology developed at the St Petersburg Forest Technical Academy. It completed phased clinical trials as a treatment for chronic liver disease in 2004.
Solagran is using its technology to produce an entire family of pharmaceuticals that it calls Bioeffectives. All of the Bioeffectives have multiple potential applications. Ropren is the finished dose form of Bioeffective R.
Click here to read the rest of today's news stories.